Two Seas Capital LP Takes Position in Nektar Therapeutics $NKTR

Two Seas Capital LP acquired a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 745,185 shares of the biopharmaceutical company’s stock, valued at approximately $31,506,000. Nektar Therapeutics comprises about 0.6% of Two Seas Capital LP’s portfolio, making the stock its 19th largest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of NKTR. BNP Paribas Financial Markets raised its stake in shares of Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Nektar Therapeutics during the second quarter valued at about $65,000. Integrated Wealth Concepts LLC bought a new position in shares of Nektar Therapeutics during the first quarter valued at about $68,000. Compass Wealth Management LLC bought a new position in shares of Nektar Therapeutics during the third quarter valued at about $88,000. Finally, Bessemer Group Inc. raised its stake in shares of Nektar Therapeutics by 1,741.2% during the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,480 shares during the last quarter. 75.88% of the stock is owned by institutional investors.

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 444 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $65.51, for a total transaction of $29,086.44. Following the completion of the transaction, the chief executive officer owned 75,045 shares of the company’s stock, valued at approximately $4,916,197.95. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. BTIG Research increased their price target on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Wedbush decreased their price target on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, May 11th. HC Wainwright increased their price target on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $149.63.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $57.32 on Friday. Nektar Therapeutics has a fifty-two week low of $7.99 and a fifty-two week high of $109.00. The company has a 50 day simple moving average of $75.88 and a two-hundred day simple moving average of $62.22. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -6.81 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. The business had revenue of $10.86 million for the quarter, compared to the consensus estimate of $10.69 million. On average, analysts forecast that Nektar Therapeutics will post -9.45 earnings per share for the current fiscal year.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.